AVE 0657

Drug Profile

AVE 0657

Alternative Names: AVE-0657

Latest Information Update: 05 May 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Class Sleep disorder therapies
  • Mechanism of Action Sodium hydrogen antiporter inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Respiration disorders; Sleep apnoea syndrome

Most Recent Events

  • 29 Apr 2009 Discontinued - Phase-II for Respiration disorders in European Union (PO)
  • 29 Apr 2009 Discontinued - Phase-II for Sleep apnoea syndrome in European Union (PO)
  • 13 Feb 2007 Phase-I clinical trials in Sleep apnoea syndrome in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top